选择性5-羟色胺再摄取抑制剂与非心源性栓塞性缺血性卒中风险:一项巢式病例对照研究
在西班牙初级医疗数据库中开展2001至2015年巢式病例对照研究,纳入8296例非心源性栓塞性缺血性卒中病例和37272例匹配对照,比较当前使用SSRIs与非使用、既往使用及其他抗抑郁药当前使用者的调整比值比。结果显示SSRIs使用与非心源性栓塞性缺血性卒中风险升高无关,与其他抗抑郁药相比似乎具有保护作用。
要点
- 当前使用SSRIs者相比非使用者,调整OR为1.14(95%CI 0.97-1.34),未达统计学显著。
- 当前使用SSRIs者相比其他抗抑郁药当前使用者,调整OR为0.74(95%CI 0.58-0.93)。
- 按持续时间、性别、年龄及背景血管风险分层未见相关差异。
核心结论
- SSRIs的使用与非心源性栓塞性缺血性卒中风险升高无关;相反,与其他抗抑郁药相比,SSRIs似乎具有保护作用。
研究设计与样本
- 在西班牙初级医疗数据库中开展的巢式病例对照研究,研究期为2001至2015年。
- 病例为无心脏栓塞性或异常原因的缺血性卒中患者,每个病例随机匹配最多5名对照(按精确年龄、性别和索引日期匹配)。
- 共纳入8296例病例和37272例匹配对照,仅考虑SSRIs和其他抗抑郁药的初始使用者。
主要发现
- 病例中当前使用SSRIs者255例(3.07%),对照中834例(2.24%)。
- 当前使用SSRIs者相比非使用者,调整OR为1.14(95%CI 0.97-1.34)。
- 当前使用SSRIs者相比既往使用者,调整OR为0.94(95%CI 0.77-1.13)。
- 当前使用SSRIs者相比其他抗抑郁药当前使用者,调整OR为0.74(95%CI 0.58-0.93)。
- 按持续时间(≤1年、>1年)、性别、年龄(<70岁、≥70岁)及背景血管风险分层,未发现相关差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple studies have reported that the use of selective serotonin reuptake inhibitors (SSRIs) is associated with an increased risk of ischemic stroke; however, this finding may be the result of a confounding by indication. We examined the association using different approaches to minimize such potential bias. METHODS: A nested case-control study was carried out in a Spanish primary health-care database over the study period 2001 to 2015. Cases were patients sustaining an ischemic stroke with no sign of cardioembolic or unusual cause. For each case, up to 5 matched controls (for exact age, sex, and index date) were randomly selected. Antidepressants were divided in 6 pharmacological subgroups according to their mechanism of action. The current use of SSRIs (use within a 30-day window before index date) was compared with nonuse, past use (beyond 365 days) and current use of other antidepressants through a conditional logistic regression model to obtain adjusted odds ratios and 95% CI. Only initiators of SSRIs and other antidepressants were considered. RESULTS: A total of 8296 cases and 37 272 matched controls were included. Of them, 255 (3.07%) were current users of SSRIs among cases and 834 (2.24%) among controls, yielding an adjusted odds ratio of 1.14 (95% CI, 0.97-1.34) as compared with nonusers, 0.94 (95% CI, 0.77-1.13) as compared with past-users and 0.74 (95% CI, 0.58-0.93) as compared with current users of other antidepressants. No relevant differences were found by duration (≤1, >1 year), sex, age (<70, ≥70 years old) and background vascular risk. CONCLUSIONS: The use of SSRIs was not associated with an increased risk of noncardioembolic ischemic stroke. On the contrary, as compared with other antidepressants, SSRIs appeared to be protective.
引用
- Alqdwah-Fattouh R, Rodríguez-Martín S, Barreira-Hernández D, et al. Selective Serotonin Reuptake Inhibitors and Risk of Noncardioembolic Ischemic Stroke: A Nested Case-Control Study. Stroke. 2022. PMID: 35109681. doi:10.1161/STROKEAHA.121.036661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。